UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of November 2025
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
c/o
Meitar Law Offices Abba Hillel Silver Rd.,
Ramat
Gan, 5250608
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
November 18, 2025, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed Announces Meaningful Top Line Results from
AM-001 Study of Aramchol Meglumine.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
EXHIBIT
INDEX
Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Press Release, dated November 18, 2025. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Galmed Pharmaceuticals Ltd. |
| |
|
|
| Date: November 18, 2025 |
By: |
/s/ Allen
Baharaff |
| |
|
Allen Baharaff |
| |
|
President and Chief Executive Officer |
